The U.S. Food and Drug Administration (FDA) added a warning earlier this month to "puberty blocker" gonadotropin-releasing hormone (GnRH) agonists after six cases "were identified that supported a plausible association between GnRH agonist use and pseudotumor cerebri."
In layman's terms, this means the drugs could cause swelling of the brain and vision loss.
A spokesperson for the FDA also said the cases are "clinically serious." The products in question include Lupron Depot-Ped, Fensolvi, Synarel, Supprelin LA, and Triptodur.
"All six cases were reported in birth-assigned females ages 5 to 12 years," the FDA said. "Five were undergoing treatment for central precocious puberty and one for transgender care," the FDA said.
Notice that the FDA refers to girls as "birth-assigned females," and child abuse as "transgender care."
"The onset of pseudotumor cerebri symptoms ranged from three to 240 days after GnRH agonist initiation," the FDA said. "Symptoms included visual disturbances (n=5), headache or vomiting (n=5), papilledema (n=3), blood pressure increase (n=1) and abducens neuropathy (n=1)."
"At the time of the FDA's review, symptoms had resolved in three patients, were resolving in one patient, had not resolved in one patient, and one patient's status was unknown. GnRH agonist therapy was discontinued in three patients; the status of continued therapy was unknown for the remaining three patients."
How about we discontinue this for all boys and girls everywhere, forever?
P.S. Now check out our latest video 👇
